%0 Journal Article %A José M Álvaro-Gracia %A Carlos Sanchez-Piedra %A Dante Culqui %A Rosa Rosello %A Alicia Garcia-Dorta %A Cristina Campos %A Sara Manrique-Arija %A Dolores Ruiz-Montesinos %A Inmaculada Ros-Vilamajo %A Carlos Rodríguez-Lozano %A Mercedes Freire-González %A Rafael Caliz %A Cristina Bohorquez %A Lourdes Mateo Soria %A Noemí Busquets %A Isabel Castrejon %A Fernando Sánchez-Alonso %A Enrique González-Dávila %A Federico Diaz-Gonzalez %T Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study %D 2023 %R 10.1136/rmdopen-2022-002936 %J RMD Open %P e002936 %V 9 %N 1 %X Objective To investigate the influence of COVID-19 vaccination on disease activity in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients under targeted therapies.Patients and methods 1765 vaccinated patients COVID-19, 1178 (66.7%) with RA and 587 (33.3%) with PsA from the COVID-19 registry in patients with rheumatic diseases (COVIDSER) project, were included. Demographics, disease characteristics, Disease Activity Score in 28 joints (DAS28) and targeted treatments were collected. DAS28-based flare rates and categorised disease activity distribution prevaccination and post vaccination were analysed by log-linear regression and contingency analyses, respectively. The influence of vaccination on DAS28 variation as a continuous measure was evaluated using a random coefficient model.Results The distribution of categorised disease activity and flare rates was not significantly modified by vaccination. Log-linear regression showed no significant changes in the rate of flares in the 6-month period after vaccination compared with the same period prior to vaccination in neither patients with RA nor patients with PsA. When DAS28 variations were analysed using random coefficient models, no significant variations in disease activity were detected after vaccination for both groups of patients. However, patients with RA treated with Janus kinase inhibitors (JAK-i) (1) and interleukin-6 inhibitor (IL-6-i) experienced a worsening of disease activity (1.436±0.531, p=0.007, and 1.201±0.550, p=0.029, respectively) in comparison with those treated with tumour necrosis factor inhibitor (TNF-i). Similarly, patients with PsA treated with interleukin-12/23 inhibitor (IL-12/23-i) showed a worsening of disease activity (4.476±1.906, p=0.019) compared with those treated with TNF-i.Conclusion COVID-19 vaccination was not associated with increased rate of flares in patients with RA and PsA. However, a potential increase in disease activity in patients with RA treated with JAK-i and IL-6-i and in patients with PsA treated with IL-12/23-i warrants further investigation.Data are available upon reasonable request. Data are available on reasonable request. The data supporting the results of this study are the property of the Spanish Society of Rheumatology (SER) and are not publicly available. However, the data are released upon reasoned request and with the permission of the SER. %U https://rmdopen.bmj.com/content/rmdopen/9/1/e002936.full.pdf